Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nephros (NEPH) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Nephros (NEPH) over the last 16 years, with Q1 2025 value amounting to $6000.0.

  • Nephros' Gains from Investment Securities rose 20000.0% to $6000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $6000.0, marking a year-over-year decrease of 9949.24%. This contributed to the annual value of $1.2 million for FY2024, which is 988.91% down from last year.
  • Nephros' Gains from Investment Securities amounted to $6000.0 in Q1 2025, which was up 20000.0% from $18000.0 recorded in Q3 2024.
  • In the past 5 years, Nephros' Gains from Investment Securities registered a high of $1.2 million during Q4 2023, and its lowest value of $2000.0 during Q1 2023.
  • Its 5-year average for Gains from Investment Securities is $157142.9, with a median of $10500.0 in 2021.
  • Per our database at Business Quant, Nephros' Gains from Investment Securities skyrocketed by 37142.86% in 2022 and then plummeted by 9696.97% in 2023.
  • Nephros' Gains from Investment Securities (Quarter) stood at $223000.0 in 2021, then soared by 202.24% to $674000.0 in 2022, then soared by 72.11% to $1.2 million in 2023, then tumbled by 98.45% to $18000.0 in 2024, then plummeted by 66.67% to $6000.0 in 2025.
  • Its Gains from Investment Securities stands at $6000.0 for Q1 2025, versus $18000.0 for Q3 2024 and $2000.0 for Q2 2024.